| 免疫检查点抑制剂联合治疗：从机制到临床 |
| |
| 引用本文： | 朱晓东,陈思元.免疫检查点抑制剂联合治疗：从机制到临床[J].中国癌症杂志,2020,30(12):969-976. |
| |
| 作者姓名： | 朱晓东 陈思元 |
| |
| 作者单位： | 复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系，上海 200032 |
| |
| 摘 要： | 近年来免疫检查点抑制剂（immune checkpoint inhibitor，ICI）陆续获批用于多种恶性肿瘤的治疗，为患者带来新的希望。但在一些瘤种中ICI单药客观缓解率仅10%~20%，如何提高临床获益是免疫相关临床研究关注的重点。近期研究显示，联合不同机制的ICI有助于提高缓解率和发挥持久的抗肿瘤作用，合适的剂量方案也能合理平衡疗效和安全性。拟对ICI联合治疗的机制、药代动力学和临床研究进展进行综述。
|
| 关 键 词： | 免疫疗法 程序性死亡［蛋白］-1 细胞毒性T淋巴细胞相关蛋白4 黑色素瘤 胃肠道肿瘤 肺肿瘤 |
Combination therapy of immune checkpoint inhibitors: from rationale to practice |
| |
| ZHU Xiaodong,CHEN Siyuan.Combination therapy of immune checkpoint inhibitors: from rationale to practice[J].China Oncology,2020,30(12):969-976. |
| |
| Authors: | ZHU Xiaodong CHEN Siyuan |
| |
| Affiliation: | Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China; |
| |
| Abstract: | In recent years, immune checkpoint inhibitors (ICIs) have been approved for the treatment of various malignanttumors. However, the objective response rate of ICIs monotherapy is relatively low (only 10% to 20% in specific populations).Improving clinical benefit in patients receiving ICIs has always been the focus of immune-related clinical research. Recent studieshave demonstrated that combining ICIs of different mechanisms might increase the response rates as well as prolong the duration ofresponse. And using appropriate dosage regimens could reasonably balance efficacy and safety of ICIs. We aimed to summarize themechanism, pharmacokinetics, and efficacy and safety results from clinical trials for combination therapy with ICIs. |
| |
| Keywords: | Immunotherapy Programmed death-1 Cytotoxic T-lymphocyte-associated protein 4 Melanoma Gastrointestinal neoplasms Lung neoplasms
|
|
| 点击此处可从《中国癌症杂志》浏览原始摘要信息 |
|
点击此处可从《中国癌症杂志》下载全文 |
